Briefs: Zydus, Divi's Laboratories and Relonchem

FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations

FDA concludes Lupin’s Nagpur Unit-1 facility inspection with zero observations

Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY

EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025

Kilitch Drugs H! FY26 PAT up 18% YoY to Rs. 10.30 Cr

Total income for the period stood at Rs. 7101.28 crore

Lupin receives EIR from FDA for its Aurangabad facility

The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.

Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities

The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million

Shilpa Medicare announces positive Phase 3 results for Oeris

OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days

Granules Life Sciences receives first FDA approval for Hyderabad facility

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy

Marksans Pharma's Goa unit clears FDA inspection

The said inspection concluded with Zero Form 483 observation